VC-backed Beam Therapeutics debuts IPO
Cambridge, Massachusetts-based Beam Therapeutics, a developer of precision genetic medicines, has raised about $180 million for its IPO after pricing its over 10 million shares at $17 per share.
Cambridge, Massachusetts-based Beam Therapeutics, a developer of precision genetic medicines, has raised about $180 million for its IPO after pricing its over 10 million shares at $17 per share.
Copyright PEI Media
Not for publication, email or dissemination